Trials / Completed
CompletedNCT00404573
Study Evaluating RGH-188 in the Treatment of Patients With Schizophrenia
A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of RGH-188 in the Acute Exacerbation of Schizophrenia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 375 (estimated)
- Sponsor
- Forest Laboratories · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a study designed to evalute the safety and efficacy of RGH-188 in the treatment of acute schizophrenia. This study will be 10 weeks in duration; 6 weeks double-blind treatment, and 4 weeks safety follow-up. All patients meeting the eligibility criteria will be randomized to one of the three treatment groups--one of two doses of RGH-188 or placebo
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RGH-188 |
Timeline
- Start date
- 2006-11-01
- Primary completion
- 2007-08-01
- First posted
- 2006-11-29
- Last updated
- 2008-01-07
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00404573. Inclusion in this directory is not an endorsement.